Home>>Signaling Pathways>> Endocrinology and Hormones>> Thyroid hormone Receptor>>Eprotirome (KB2115)

Eprotirome (KB2115) (Synonyms: Eprotirome)

Catalog No.GC33764

Eprotirome (KB2115) (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist.

Products are for research use only. Not for human use. We do not sell to patients.

Eprotirome (KB2115) Chemical Structure

Cas No.: 355129-15-6

Size Price Stock Qty
10mM (in 1mL DMSO)
$985.00
In stock
1mg
$184.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Eprotirome is a liver-selective thyroid hormone receptor agonist.

Eprotirome is a liver-selective thyroid hormone receptor agonist. Histological analysis of livers from mice treated with Eprotirome reveals that Eprotirome elicits a near complete elimination of lipid filled vacuoles that are characteristic of the livers from untreated control mice. Eprotirome treated mice also exhibit increased fasting glucose, but Eprotirome does not increase fasting insulin levels. Glucose levels of mice treated with Eprotirome continues to increase over time, leading to pronounced hyperglycemia by the end of the study. Temperature of mice treated with Eprotirome is decreased relative to untreated control mice[1].

[1]. Martagón AJ, et al. The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. PLoS One. 2015 Apr 7;10(4):e0122987.

Reviews

Review for Eprotirome (KB2115)

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eprotirome (KB2115)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.